Just saw WuXi Biologics (HK:2269) popped 3% on news of a collab with Vertex Pharma. They're working on some trispecific T-cell Engager tech for autoimmune diseases, which honestly sounds pretty serious stuff. Vertex gets the exclusive global rights to develop and commercialize it, while WuXi gets upfront cash plus milestone and royalty payments. Pretty standard pharma deal structure.

What caught my eye though is that Vertex is already deep into myotonic dystrophy treatments and other rare disease research, so this partnership actually makes sense for them. WuXi's known for their integrated platforms and they're supporting like 945 client projects including a bunch in Phase III trials. The fact that they're also providing contract R&D services on next-gen TCEs suggests this could be a longer-term relationship.

As of late last year, WuXi had been trading between HK$16.20 and HK$42.60, so this move above HK$36 shows some confidence. Vertex side is less volatile but also sitting pretty. Not sure if this is a one-off spike or if there's more momentum here, but the biotech sector seems to be picking up on these kinds of deals lately. Anyone else watching the CDMO space?